PTC Therapeutics (PTCT) was recently added to three Russell 2000 Defensive indexes, including value and growth focused ...
Zacks Investment Research on MSN
PTC Therapeutics (PTCT) upgraded to strong buy: Here's what you should know
PTC Therapeutics (PTCT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces ...
PTC Therapeutics stock has delivered a 116.6% return over the past three years, yet current valuation checks suggest the ...
PTC Therapeutics is entering a new phase following the launch of Sephience, with expanding commercial efforts and pipeline development shaping the company's next chapter.
PTC (NASDAQ: PTC) will release its fiscal 2026 third quarter results on Wednesday, July 29 th after the stock market closes.
Barchart on MSN
PTC Inc. earnings preview: What to expect
PTC Inc. (PTC), headquartered in Boston, Massachusetts, develops and delivers technology solutions, comprised of software and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results